DexCom, Inc. (DXCM) Presents At 2025 Wells Fargo Healthcare Conference (Transcript)
DexCom, Inc. (NASDAQ:DXCM ) 2025 Wells Fargo Healthcare Conference September 3, 2025 2:15 PM EDT Company Participants Jacob Leach - President & COO Jereme Sylvain - Executive VP, CFO & Chief Accounting Officer Conference Call Participants Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Presentation Larry Biegelsen Senior Medical Device Equity Research Analyst Welome back. I am Larry Biegelsen, medical device analyst at Wells Fargo.
Why Is DexCom (DXCM) Down 7% Since Last Earnings Report?
DexCom (DXCM) reported earnings 30 days ago. What's next for the stock?
DexCom Expands Access and Innovation While Balancing Headwinds
DXCM grows on type 2 access, Stelo adoption, and new sensor launches, but faces margin pressures, competition and leadership transition.
DexCom Stock Falls Despite Q2 Earnings Beat & 2025 Sales View Raise
DXCM beats on Q2 earnings and raises 2025 sales guidance, but shares dip as margin pressure dampens investor enthusiasm.
DexCom, Inc. (DXCM) Q2 2025 Earnings Call Transcript
DexCom, Inc. (NASDAQ:DXCM ) Q2 2025 Earnings Conference Call July 30, 2025 4:30 PM ET Company Participants Jacob Steven Leach - President & COO Jereme M. Sylvain - Executive VP, CFO & Chief Accounting Officer Kevin Ronald Sayer - Executive Chairman & CEO Sean Christensen - Vice President of Finance and Investor Relations Conference Call Participants Brandon Vazquez - William Blair & Company L.L.C.
Compared to Estimates, DexCom (DXCM) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for DexCom (DXCM) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
DexCom (DXCM) Q2 Earnings and Revenues Top Estimates
DexCom (DXCM) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.43 per share a year ago.
DexCom (DXCM) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
Besides Wall Street's top-and-bottom-line estimates for DexCom (DXCM), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
Will DXCM Q2 Earnings Reflect U.S. Coverage Expansion & Stelo Impact?
DexCom Q2 results are likely to reflect strong growth on the back of coverage by two large PBMs and Stelo traction, driving momentum and market expansion in 2025.
DexCom: Delivering Consistent Growth
DexCom focuses on continuous glucose monitoring systems, with a strong market position and global reach. Q1 results showed 13% revenue growth, beating expectations, though earnings were slightly below consensus. Analysts remain bullish, with most issuing Buy ratings and price targets ranging from $87 to $110 per share.
Are Medical Stocks Lagging DexCom (DXCM) This Year?
Here is how DexCom (DXCM) and Amarin (AMRN) have performed compared to their sector so far this year.
DexCom (DXCM) Upgraded to Strong Buy: Here's What You Should Know
DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
